Region:Middle East
Author(s):Dev
Product Code:KRAC1969
Pages:85
Published On:October 2025
By Type:The market is segmented into various types of clinical trials, including Phase I Trials, Phase II Trials, Phase III Trials, Phase IV Trials, Observational Studies, Registry Studies, and Others. Each of these trial phases plays a crucial role in the drug development process, with Phase III Trials being particularly significant due to their focus on efficacy and safety in larger populations. Phase III trials dominate the UAE market, accounting for the largest segment with substantial revenue share, reflecting the country's capacity to conduct large-scale efficacy studies. The UAE has witnessed increased adoption of decentralized and hybrid trial models utilizing eConsent, home-based assessments, wearables, and imaging biomarkers, resulting in shorter cycle times and improved patient retention rates.
By Indication:The market is also segmented by indications, including Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Epilepsy, Stroke, Migraine, and Others. Alzheimer's Disease and Parkinson's Disease are particularly prominent due to their high prevalence and the urgent need for effective treatments, driving significant research efforts in these areas. Alzheimer's Disease holds particular importance in the UAE, with the country ranked second globally for the highest percentage of people suffering from dementia according to a Lancet study published in 2022, significantly boosting demand for dementia research and clinical trials in neurological disorders. Regional activity predominantly focuses on Phase II trials for neurodegeneration and pain, while Phase III programs have emerged for multiple sclerosis, epilepsy, and migraine, with registries for device-assisted stroke and movement disorders also prominent.
The UAE Neurology Clinical Trials Market is characterized by a dynamic mix of regional and international players. Leading participants such as Abu Dhabi Clinical Trials Center, Dubai Health Authority, Gulf Clinical Research, Al Ain Hospital, Emirates Clinical Research Institute, Medcare Hospitals, Cleveland Clinic Abu Dhabi, Sheikh Khalifa Medical City, Dubai Science Park, Abu Dhabi University, University of Sharjah, RAK Hospital, Mediclinic City Hospital, Aster DM Healthcare, NMC Healthcare contribute to innovation, geographic expansion, and service delivery in this space.
The future of the UAE neurology clinical trials market appears promising, driven by increasing investments in healthcare innovation and a growing focus on patient-centric trial designs. As the prevalence of neurological disorders continues to rise, the demand for effective treatments will propel research initiatives. Furthermore, the integration of telemedicine and decentralized trial methodologies is expected to enhance patient recruitment and retention, ultimately leading to more successful trial outcomes and a robust clinical research environment.
| Segment | Sub-Segments |
|---|---|
| By Type | Phase I Trials Phase II Trials Phase III Trials Phase IV Trials Observational Studies Registry Studies Others |
| By Indication | Alzheimer's Disease Parkinson's Disease Multiple Sclerosis Epilepsy Stroke Migraine Others |
| By Phase | Early Phase Trials Late Phase Trials Post-Marketing Studies Others |
| By Geography | Abu Dhabi Dubai Sharjah Ajman Ras Al Khaimah Fujairah Others |
| By Sponsor Type | Pharmaceutical Companies Biotechnology Firms Academic Institutions Government Agencies Contract Research Organizations (CROs) Others |
| By Patient Demographics | Age Group Gender Socioeconomic Status Others |
| By Funding Source | Public Funding Private Funding Non-Profit Organizations Others |
| Scope Item/Segment | Sample Size | Target Respondent Profiles |
|---|---|---|
| Neurology Clinical Trial Coordinators | 45 | Clinical Research Coordinators, Trial Managers |
| Neurologists in UAE Hospitals | 40 | Consultant Neurologists, Attending Physicians |
| Pharmaceutical Companies Conducting Trials | 40 | Clinical Development Managers, Regulatory Affairs Specialists |
| Patients Participating in Trials | 50 | Trial Participants, Patient Advocacy Group Members |
| Healthcare Policy Makers | 40 | Health Economists, Policy Analysts |
The UAE Neurology Clinical Trials Market is valued at approximately USD 1.2 billion, reflecting significant growth driven by the rising prevalence of neurological disorders and advancements in clinical research methodologies.
What makes us stand out is that our consultants follow Robust, Refine and Result (RRR) methodology. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents' facts and opinions, and Result for presenting data with story.
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.
